Net income turned positive to $6.3 million compared to a loss in the prior year period.
Gross margins remained flat at 67.7% despite price increases, as COGS rose 27.6%.
Repurchased $8.8 million of Class A common stock in Q1 2026.
Maintains a $100 million revolving credit facility with no current outstanding borrowings.
The Q1 2026 filing presents a company at a crossroads between successful brand scaling and operational instability. On one hand, the revenue growth and customer acquisition numbers are impressive, suggesting that the 'lifestyle' pivot for healthcare apparel is resonating with the market. The shift to positive net income and adjusted EBITDA provides a baseline for a bullish case centered on operational leverage and brand dominance. However, the divergence between GAAP net income and free cash flow is a critical red flag. The transition to negative operating cash flow and the resulting dip in liquidity suggest that the cost of maintaining this growth—specifically through massive marketing spends and inventory builds—is weighing heavily on the balance sheet. Investors are left to weigh the strength of the brand's growth trajectory against the reality of a cash-flow squeeze and the looming uncertainty of global trade policies and tariffs.